Unichem Laboratories
543.20
-18.95(-3.37%)
Market Cap₹3,824.44 Cr
PE Ratio31.54
IndustryHealthcare
Company Performance:
1D-3.37%
1M-9.68%
6M-24.90%
1Y-3.06%
5Y+108.48%
View Company Insightsright
Latest news about Unichem Laboratories
Unichem Lab Reports Q1 Net Loss of 10.47 Crore, Revenue Rises to 526.60 Crore 1 day ago Yesterday
Unichem Laboratories reported a consolidated net loss of ₹10.47 crore in Q1, compared to a profit of ₹2.07 crore in the same quarter last year. Revenue from operations increased by 8.95% to ₹526.60 crore. EBITDA declined by 43.89% to ₹22.50 crore, with the EBITDA margin dropping to 4.27% from 8.30%. The company also extended the exercise period for vested options under its Employee Stock Option Scheme 2018 to September 30, 2026.
Unichem Labs' Roha API Facility Receives Three Form 483 Observations from USFDA Jun 23, 2025
Unichem Laboratories to Close UK Manufacturing Facility and Divest Irish Subsidiary Mar 28, 2025
Unichem Laboratories Completes Phase I API Plant Expansion, Boosts Capacity by 210 KL Mar 21, 2025
Unichem Laboratories Boosts API Capacity with ₹200 Crore Expansion at Pithampur Plant Mar 20, 2025
More news about Unichem Laboratories
02Mar 25
Unichem Laboratories' Pithampur API Facility Inspection Concludes; Company Announces Sale of Mumbai Property
Unichem Laboratories underwent a USFDA inspection at its Pithampur API facility, resulting in four procedural observations. The company will respond within 15 days. Separately, Unichem's Board approved the sale of a 3.40-acre Mumbai property to Macrotech Developers for ₹279 crores, with completion expected by June 30, 2025. The property's book value is ₹2.18 crores, indicating a significant gain from the sale.
02Mar 25
Unichem Laboratories to Sell Jogeshwari Property for Rs 279 Crore
Unichem Laboratories has approved the sale of a 3.40-acre property in Mumbai to Macrotech Developers Limited for Rs 279 crore. The property, previously the company's registered office, has a book value of Rs 2.18 crore. The transaction is expected to complete by June 30, 2025, and will not impact ongoing business operations. This move is part of Unichem's strategy to monetize non-core assets and focus on its pharmaceutical activities.
Unichem Laboratories
543.20
-18.95
(-3.37%)
1 Year Returns:-3.06%
Industry Peers
Sun Pharmaceutical
1,629.20
(-0.76%)
Divis Laboratories
6,374.50
(-1.77%)
Torrent Pharmaceuticals
3,589.90
(-0.63%)
Cipla
1,496.90
(-1.20%)
Mankind Pharma
2,603.50
(-0.97%)
Dr Reddys Laboratories
1,213.70
(-0.92%)
Zydus Life Science
958.50
(-0.04%)
Lupin
1,864.10
(-0.96%)
Abbott
33,340.00
(-1.93%)
Aurobindo Pharma
1,070.40
(-1.83%)